OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31

OnKure Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$2.25+0.15 (+7.14%)

Close on Oct 19, 2026

Market cap: $112.21M
P/E (TTM): –
Dividend yield: –

OnKure Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31
Depreciation & Amortization	0.40	0.43	0.45	0.46	0.47	0.46	0.46	0.63	0.56	0.49	0.42	0.15	0.13	0.11	0.09	0.08	0.07	0.06	0.05	0.04	0.04	0.04	0.04
Stock-Based Compensation	12	12	12	11	8.26	7.17	4.53	-1.60	-0.25	-0.85	0.20	5.01	4.57	4.37	4.32	4.52	4.68	4.53	3.89	2.60	1.54	0.77	0.39
Change in Accounts Payable	-0.74	-3.77	-4.55	-15	-15	-5.87	-5.93	0.36	0.74	-3.42	1.71	4.19	5.48	2.67	0.52	2.80	4.67	3.96	1.78	3.28	-0.61	0.52	1.49
Operating Cash Flow	-48	-51	-52	-64	-61	-54	-51	-18	-26	-36	-35	-60	-52	-47	-47	-42	-41	-38	-38	-33	-29	-23	-19
Capital Expenditures	-0.02	-0.03	-0.05	-0.05	-0.06	-0.06	-0.05	-0.09	-0.09	-0.08	-0.25	-0.45	-0.46	-0.47	-0.35	-0.19	-0.24	-0.22	-0.20	-0.12	-0.05	-0.05	-0.02
Purchase of Investments	–	–	–	–	–	–	–	-109	-167	-248	-231	-224	-218	-114	-102	-67	-20	–	-31	–	–	–	–
Sale & Maturity of Investments	–	–	–	–	–	–	16	210	264	254	242	169	96	70	44	–	–	–	–	–	–	–	7.40
Investing Cash Flow	-9.89	-0.03	-0.05	16	16	16	16	29	50	-19	-0.25	-56	-123	-45	-58	-23	18	-18	-23	-32	-26	2.15	7.38
Stock Issued	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	84	85	–	–	–	–
Financing Cash Flow	141	146	0.16	110	110	116	116	-5.99	-5.82	52	53	65	65	1.47	0.47	0.27	0.39	86	132	179	179	93	47
Net Change in Cash	83	95	-52	62	65	77	81	4.61	18	-2.76	18	-50	-109	-91	-105	-64	-22	30	71	115	124	73	36
Free Cash Flow	-48	-51	-52	-64	-61	-55	-51	-18	-27	-36	-35	-60	-52	-48	-48	-42	-41	-39	-38	-33	-29	-23	-19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -74.4%

Financial strength

Current ratio: 26.75
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2506.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.65
Dividend yield: –